Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06681220
Title Biomarker Directed Trial of Temozolomide and PARP Inhibition in Relapsed SCLC (Relapsed SCLC)
Acronym Relapsed SCLC
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors VA Office of Research and Development
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.